- $48.67m
- $129.31m
- $83.81m
U.S. STOCKS ON THE MOVE-Gene therapy cos, gold miners, chipmakers
Bluebird bio rises on non-binding bid for up to $110.5 million
Bluebird bio receives non-binding bid for up to $110.5 million
Bluebird Bio shares rally 11% in late trade on buyout offer
Brief: Bluebird Bio Confirms Receipt Of An Unsolicited Non-Binding Proposal From Ayrmid
bluebird bio Inc reports results for the quarter ended December 31 - Earnings Summary
bluebird bio Inc expected to post a loss of $6.15 a share - Earnings Preview
Focus: Gene therapy loses luster as investors eye quicker returns from weight-loss drugs
J.P. Morgan upgrades bluebird bio to 'neutral'
U.S. RESEARCH ROUNDUP-Amneal pharma, Aramark, Bluebird Bio
U.S. STOCKS ON THE MOVE-MP Materials, Five9, Alphabet
U.S. STOCKS ON THE MOVE-MercadoLibre, CrowdStrike Holdings, Protagonist Therapeutics
U.S. STOCKS ON THE MOVE-Acelyrin, Bluebird bio, Coinbase
Brief: Bluebird Bio Announces Definitive Agreement To Be Acquired By Carlyle And SK Capital
Bluebird bio falls on discounted take private deal with Carlyle, SK Capital
Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch (updated)
Bluebird bio agrees to be acquired by Carlyle and SK Capital
Brief: Bluebird Bio Inc - On Feb 13 Terminates Sublease Agreement With Aventis, Are-Ma Region No. 102 Owner And Meta
U.S. RESEARCH ROUNDUP-3M, Citigroup, F5